Clinical Trials Logo

Clinical Trial Summary

To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering- Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03517943
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date April 24, 2018
Completion date August 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT02629562 - Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects Phase 1
Completed NCT02286518 - TAK-114 Single- and Multiple-Dose Phase 1 Study Phase 1
Completed NCT01473108 - Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862 Phase 1
Completed NCT03424135 - A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions Phase 1
Completed NCT05437094 - Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 Phase 1
Completed NCT02276274 - Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects Phase 3
Completed NCT03074058 - Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet Phase 1
Completed NCT04511611 - Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects Phase 1
Completed NCT04511637 - Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects Phase 1
Completed NCT02113020 - A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects Phase 1
Completed NCT04364464 - Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight Phase 1
Completed NCT06126861 - The Mass Balance Study of LP-168 in Healthy Subjects Phase 1
Completed NCT03136666 - Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design. Phase 1
Completed NCT03517930 - A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects Phase 1
Completed NCT04366622 - Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight Phase 1